Rivaroxaban (Xarelto, BAY59-7939) + Standard of care

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Deep Vein Thrombosis

Conditions

Deep Vein Thrombosis, Venous Thrombosis

Trial Timeline

Jun 1, 2012 → Jul 1, 2015

NCT ID

NCT01619007

About Rivaroxaban (Xarelto, BAY59-7939) + Standard of care

Rivaroxaban (Xarelto, BAY59-7939) + Standard of care is a pre-clinical stage product being developed by Bayer for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01619007. Target conditions include Deep Vein Thrombosis, Venous Thrombosis.

What happened to similar drugs?

4 of 12 similar drugs in Deep Vein Thrombosis were approved

Approved (4) Terminated (2) Active (8)

✅Dalteparin sodium injection + WarfarinPfizerApproved

✅Low Molecular Weight Heparin (dalteparin)PfizerApproved

✅ApixabanPfizerApproved

✅ClexaneSanofiApproved

🔄Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3

🔄Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3

🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01619007	Pre-clinical	Completed	Jun 1, 2012	Jul 1, 2015	Deep Vein Thrombosis
NCT01947959	Pre-clinical	Completed	Dec 22, 2011	Sep 30, 2020	Venous Thrombosis

Competing Products

20 competing products in Deep Vein Thrombosis

See all competitors

Product	Company	Stage	Hype Score
Edoxaban low dose + Edoxaban high dose	Daiichi Sankyo	Phase 1	29
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 2	35
Fragmin (dalteparin sodium )	Pfizer	Pre-clinical	26
Fluconazole	Pfizer	Pre-clinical	26
Dalteparin sodium injection + Warfarin	Pfizer	Approved	43
Low Molecular Weight Heparin (dalteparin)	Pfizer	Approved	43
Apixaban + Unfractionated Heparin (UFH) + Warfarin	Pfizer	Phase 3	40
Apixaban	Pfizer	Approved	35
Apixaban	Bristol Myers Squibb	Phase 2	35
Enoxaparin + Placebo + Apixaban + Placebo	Bristol Myers Squibb	Phase 3	40
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	40
Apixaban	Bristol Myers Squibb	Pre-clinical	26
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	40
Enoxaparin	Sanofi	Pre-clinical	26
Clexane	Sanofi	Approved	35
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)	Sanofi	Phase 3	40
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)	Sanofi	Phase 3	40
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + Warfarin	Bayer	Phase 3	37
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines	Bayer	Pre-clinical	23
Triptorelin Acetate 3.75mg intramuscular injection	Ipsen	Pre-clinical	23